Citations (153)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Enrique Alvarez, Kavita V. Nair, Hiangkiat Tan, Kapil Rathi, Nicole B. Gabler, Eric M. Maiese, Chinmay Deshpande & Qiujun Shao. (2023) Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies. Journal of Medical Economics 26:1, pages 494-502.
Read now
Read now
Niall Russell, Stephen Gallagher, Rachel M. Msetfi, Sara Hayes, Robert W. Motl & Susan Coote. (2023) Experiences of people with multiple sclerosis participating in a social cognitive behavior change physical activity intervention. Physiotherapy Theory and Practice 39:5, pages 954-962.
Read now
Read now
Nupur Greene, Keiko Higuchi, Katalin Bognar, Eunice Chang & Michael S Broder. (2022) Medication Adherence and Healthcare Utilization in Relapsing-Remitting Multiple Sclerosis Patients Using Teriflunomide. ClinicoEconomics and Outcomes Research 14, pages 755-761.
Read now
Read now
Dirk Schriefer, Rocco Haase, Nils-Henning Ness & Tjalf Ziemssen. (2022) Cost of illness in multiple sclerosis by disease characteristics – A review of reviews. Expert Review of Pharmacoeconomics & Outcomes Research 22:2, pages 177-195.
Read now
Read now
Olivier Vandhuick, Marianne Payet, Emmanuelle Préaud, Joannie Lortet-Tieulent, Fanny Raguideau, Olivier Chevreuil, Benoit van Hille & Arnaud Kwiatkowski. (2021) Economic burden of highly active relapsing-remitting multiple sclerosis patients in the French national health insurance database. Expert Review of Pharmacoeconomics & Outcomes Research 21:5, pages 1135-1144.
Read now
Read now
Surachat Ngorsuraches & Nabin Poudel. (2021) Incorporating patients’ preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review. Expert Review of Pharmacoeconomics & Outcomes Research 21:2, pages 183-195.
Read now
Read now
Regina Berkovich, Edward Fox, Annette Okai, Yao Ding, Magdaliz Gorritz, Lauren Bartolome, Rolin L. Wade, Wendy Su, Kristen M. Johnson & Patricia Russo. (2021) Identifying disability level in multiple sclerosis patients in a U.S.-based health plan claims database. Journal of Medical Economics 24:1, pages 46-53.
Read now
Read now
Kaoru Yamabe, Marco D DiBonaventura & Chris L Pashos. (2019) Health-related outcomes, health care resource utilization, and costs of multiple sclerosis in Japan compared with US and five EU countries. ClinicoEconomics and Outcomes Research 11, pages 61-71.
Read now
Read now
Mehdi Rezaee, Sadegh Izadi, Khosro Keshavarz, Afshin Borhanihaghighi & Ramin Ravangard. (2019) Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran. Journal of Medical Economics 22:4, pages 297-305.
Read now
Read now
Duygu Bozkaya, Terrie Livingston, Kristen Migliaccio-Walle & Tanner Odom. (2017) The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis. Journal of Medical Economics 20:3, pages 297-302.
Read now
Read now
Amy Guo, Michael Grabner, Swetha Rao Palli, Jessica Elder, Matthew Sidovar, Peter Aupperle & Stephen Krieger. (2016) Treatment patterns and health care resource utilization associated with dalfampridine extended release in multiple sclerosis: a retrospective claims database analysis. ClinicoEconomics and Outcomes Research 8, pages 177-186.
Read now
Read now
Aseel Bin Sawad, Enrique Seoane-Vazquez, Rosa Rodriguez-Monguio & Fatema Turkistani. (2016) Price analysis of multiple sclerosis disease-modifying therapies marketed in the United States. Current Medical Research and Opinion 32:11, pages 1783-1788.
Read now
Read now
Xuehua Ke, Prakash Navaratnam, Rahul Sasane, Debra F. Eisenberg Lawrence, Howard S. Friedman, Bernard B. Tulsi & Timothy Vollmer. (2016) Determinants of high cost in multiple sclerosis patients: a claims and chart review study. Current Medical Research and Opinion 32:9, pages 1589-1597.
Read now
Read now
Ian T Rossman & Jeffrey A Cohen. (2016) Should MRI be the primary endpoint of phase 3 trials in multiple sclerosis?. Expert Review of Clinical Immunology 12:5, pages 489-491.
Read now
Read now
George H. Kraft, Dagmar Amtmann, Susan E. Bennett, Marcia Finlayson, Matthew H. Sutliff, Mark Tullman, Matthew Sidovar & Adrian L. Rabinowicz. (2014) Assessment of Upper Extremity Function in Multiple Sclerosis: Review and Opinion. Postgraduate Medicine 126:5, pages 102-108.
Read now
Read now
Articles from other publishers (138)
Marion SchaufHarini ChinthapatlaSeema DimriEdward LiDaniel M. Hartung. (2023) Economic burden of multiple sclerosis in the United States: A systematic literature review. Journal of Managed Care & Specialty Pharmacy 29:12, pages 1354-1368.
Crossref
Crossref
Alyssa Nylander, Annika Anderson, William Rowles, Stephanie Hsu, Ann A. Lazar, Sonia R. Mayoral, Sarah E. Pease-Raissi, Ari Green & Riley Bove. (2023) Re-WRAP (Remyelination for women at risk of axonal loss and progression): A phase II randomized placebo-controlled delayed-start trial of bazedoxifene for myelin repair in multiple sclerosis. Contemporary Clinical Trials 134, pages 107333.
Crossref
Crossref
Caroline K. Geiger, Danny Sheinson, Tu My To, David Jones & Nicole G. Bonine. (2023) Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab. Neurology and Therapy 12:5, pages 1709-1728.
Crossref
Crossref
Seyed Farzad Maroufi, Parnian Shobeiri, Esmaeil Mohammadi, Sina Azadnajafabad, Mohammad-Reza Malekpour, Erfan Ghasemi, Mohammad-Mahdi Rashidi, Sahar Saeedi Moghaddam, Nazila Rezaei, Yeganeh Sharifnejad Tehrani, Sahar Mohammadi Fateh, Naser Ahmadi, Yosef Farzi, Negar Rezaei & Bagher Larijani. (2023) A Global, Regional, and National Survey on Burden and Quality of Care Index of Multiple Sclerosis: Global Burden of Disease Systematic Analysis 1990–2019. Neuroepidemiology, pages 1-13.
Crossref
Crossref
Marek Peterka. (2023) Improved cognitive function and employment in patients with relapsing multiple sclerosis treated with ocrelizumab. Neurologie pro praxi 24:4, pages 264-267.
Crossref
Crossref
Kelly Reeve, Begum Irmak On, Joachim Havla, Jacob Burns, Martina A Gosteli-Peter, Albraa Alabsawi, Zoheir Alayash, Andrea Götschi, Heidi Seibold, Ulrich Mansmann & Ulrike Held. (2023) Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis. Cochrane Database of Systematic Reviews 2023:9.
Crossref
Crossref
Marie Hosseini, Mahsa Haghighatzadeh, Rezvan Hassanpour, Elnaz Asadollahzadeh, Nasim Rezaeimanesh, Sharareh Eskandarieh, Samira Navardi, Fereshteh Ghadiri, Abdorreza Naser Moghadasi & Mohammad Ali Sahraian. (2023) The effects of different types of smoking on recovery from attack in hospitalized multiple sclerosis patients. Clinical Neurology and Neurosurgery 232, pages 107846.
Crossref
Crossref
Soghra Goliroshan, Hassan Babamohamadi, Eesa Mohammadi, Seyed Mohammad Baghbanian & Mohammad Reza Asgari. (2023) Barriers to and Facilitators of Adjustment Among Iranian Multiple Sclerosis Patients: A Qualitative Study. Qualitative Health Research.
Crossref
Crossref
Zahra Sabahi, Amin Daei Sorkhabi, Aila Sarkesh, Amirreza Naseri, Nazli Asghar-Rezaei & Mahnaz Talebi. (2023) A systematic review of the safety and efficacy of monoclonal antibodies for progressive multiple sclerosis. International Immunopharmacology 120, pages 110266.
Crossref
Crossref
Leslie Menendez, Michael Osherov, Zeev Nitsan, Marwan Alkrenawi, Anna Gelfand, Nurit Hovel, Shmuel Appel & Ron Milo. (2023) The consequences of switching from Gilenya® to generics for fingolimod. Multiple Sclerosis and Related Disorders 74, pages 104692.
Crossref
Crossref
Camille Sabathé, Romain Casey, Sandra Vukusic, Emmanuelle Leray, Guillaume Mathey, Jérôme De Sèze, Jonathan Ciron, Sandrine Wiertlewski, Aurélie Ruet, Jean Pelletier, Hélène Zéphir, Laure Michel, Christine Lebrun-Frenay, Xavier Moisset, Eric Thouvenot, Jean-Philippe Camdessanché, Serge Bakchine, Bruno Stankoff, Abdullatif Al Khedr, Philippe Cabre, Elisabeth Maillart, Eric Berger, Olivier Heinzlef, Karolina Hankiewicz, Thibault Moreau, Olivier Gout, Bertrand Bourre, Abir Wahab, Pierre Labauge, Alexis Montcuquet, Gilles Defer, Aude Maurousset, Nicolas Maubeuge, Dalia Dimitri Boulos, Haïfa Ben Nasr, Chantal Nifle, Olivier Casez, David-Axel Laplaud & Yohann Foucher. (2022) Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system. Multiple Sclerosis Journal 29:2, pages 236-247.
Crossref
Crossref
Myadagmaa Jaalkhorol, Oyunbileg Dulamsuren, Amarsaikhan Dashtseren, Enkh-Amgalan Byambajav, Nansalmaa Khaidav, Badrangui Bat-Orgil, Anar Bold, Enkhdulguun Amgalan, Anujin Chuluunbaatar & Ikuo Tsunoda. (2023) Multiple Sclerosis in Mongolia; the First Study Exploring Predictors of Disability and Depression in Mongolian MS Patients. Pathophysiology 30:1, pages 15-26.
Crossref
Crossref
Fatih Özden, Mehmet Özkeskin & Süleyman Mert Ak. (2022) Physical exercise intervention via telerehabilitation in patients with neurological disorders: a narrative literature review. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery 58:1.
Crossref
Crossref
Dirk T. Ubbink, Olga C. Damman & Brigit A. de Jong. (2022) Shared decision-making in patients with multiple sclerosis. Frontiers in Neurology 13.
Crossref
Crossref
Steven Simoens. (2022) Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies. Frontiers in Neurology 13.
Crossref
Crossref
Nupur Greene, Lita Araujo, Cynthia Campos, Hannah Dalglish, Sarah Gibbs & Irina Yermilov. (2022) The Economic and Humanistic Burden of Pediatric-Onset Multiple Sclerosis. Journal of Health Economics and Outcomes Research 9:2.
Crossref
Crossref
Nicholas M. Beskid, Elizabeth M. Kolawole, María M. Coronel, Brandon Nguyen, Brian Evavold, Andrés J. García & Julia E. Babensee. (2022) IL-10-Functionalized Hydrogels Support Immunosuppressive Dendritic Cell Phenotype and Function. ACS Biomaterials Science & Engineering 8:10, pages 4341-4353.
Crossref
Crossref
Akhil Padarti, Amod Amritphale & William Kilgo. (2022) Readmission Rates in Patients With Multiple Sclerosis: A Nationwide Cohort Study. International Journal of MS Care 24:5, pages 218-223.
Crossref
Crossref
Hoa H Le, Jennifer Ken-Opurum, Anne LaPrade, Martine C Maculaitis & John J Sheehan. (2022) Assessment of economic burden of fatigue in adults with multiple sclerosis: An analysis of US National Health and Wellness Survey data. Multiple Sclerosis and Related Disorders 65, pages 103971.
Crossref
Crossref
Melanie Ward & Myla D. Goldman. (2022) Epidemiology and Pathophysiology of Multiple Sclerosis. CONTINUUM: Lifelong Learning in Neurology 28:4, pages 988-1005.
Crossref
Crossref
Takashi Ohashi. (2022) The impact of monoclonal antibody drugs on healthcare economics in the treatment of multiple sclerosis and neuromyelitis optica spectrum disorders. Clinical and Experimental Neuroimmunology 13:3, pages 166-171.
Crossref
Crossref
Bruno Kusznir Vitturi, Alborz Rahmani, Guglielmo Dini, Alfredo Montecucco, Nicoletta Debarbieri, Elvira Sbragia, Paolo Bandiera, Michela Ponzio, Mario Alberto Battaglia, Tommaso Manacorda, Benedetta Persechino, Giuliana Buresti, Matilde Inglese & Paolo Durando. (2022) Occupational outcomes of people with multiple sclerosis: a scoping review. BMJ Open 12:7, pages e058948.
Crossref
Crossref
Jonas Lind, Sofia Persson, Jonatan Vincent, Bertil Lindenfalk, Brant J. Oliver, Andrew D. SmithIIIIII & Boel Andersson Gäre. (2022) Contact patterns and costs of multiple sclerosis in the Swedish healthcare system—A population‐based quantitative study. Brain and Behavior 12:6.
Crossref
Crossref
Zahra Hosseini, Atefeh Homayuni & Masoud Etemadifar. (2022) Barriers to quality of life in patients with multiple sclerosis: a qualitative study. BMC Neurology 22:1.
Crossref
Crossref
Alise Carlson & Marisa P McGinley. (2022) Healthcare utilization in multiple sclerosis: Impact of disease modifying therapies and comorbidities. Multiple Sclerosis Journal 28:4, pages 499-501.
Crossref
Crossref
Tan Guojun, Xu Yan, Wang Weizhi, Wang Lihua, Li Chunyang, Zhang Xinghu, Zhou Hongyu, Dong Huiqing, Zhang Meini, Jin Tao, Yang Huan, Cui Liying & Guo Li. (2022) A multicenter study to evaluate the disease burden and health economics of inpatients with multiple sclerosis in China. Multiple Sclerosis and Related Disorders 60, pages 103732.
Crossref
Crossref
Paolo Angelo Cortesi, Ippazio Cosimo Antonazzo, Claudio Gasperini, Mihaela Nica, Daniela Ritrovato & Lorenzo Giovanni Mantovani. (2022) Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy. PLOS ONE 17:3, pages e0264123.
Crossref
Crossref
Daniel M. Hartung, Kirbee A. JohnstonJessina C. McGregorDennis N. Bourdette. (2022) Characteristics of Prescription Drug Use Among Individuals With Multiple Sclerosis in the US Medicare Population. International Journal of MS Care 24:2, pages 90-97.
Crossref
Crossref
Brant J. Oliver, Karen WalshRandall Messier, Falguni MehtaAnn CabotEric KlawiterPatricia PagnottaAndrew SolomonSarah E. England. (2022) System-Level Variation in Multiple Sclerosis Care Outcomes: Initial Findings from the Multiple Sclerosis Continuous Quality Improvement Research Collaborative. Population Health Management 25:1, pages 46-56.
Crossref
Crossref
Nupur Greene, Lita Araujo, Cynthia Campos, Hannah Dalglish, Sarah Gibbs & Irina Yermilov. (2022) The Economic and Humanistic Burden of Pediatric-Onset Multiple Sclerosis. Journal of Health Economics and Outcomes Research, pages 103-114.
Crossref
Crossref
Anne-Mette Hedeager Momsen, Lisbeth Ørtenblad & Thomas Maribo. (2022) Effective rehabilitation interventions and participation among people with multiple sclerosis: An overview of reviews. Annals of Physical and Rehabilitation Medicine 65:1, pages 101529.
Crossref
Crossref
Liang Liang, Nicole Kim, Jue Hou, Tianrun Cai, Kumar Dahal, Chen Lin, Sean Finan, Guergana Savovoa, Mattia Rosso, Mariann Polgar-Tucsanyi, Howard Weiner, Tanuja Chitnis, Tianxi Cai & Zongqi Xia. (2022) Temporal trends of multiple sclerosis disease activity: Electronic health records indicators. Multiple Sclerosis and Related Disorders 57, pages 103333.
Crossref
Crossref
Gabriel Guo, Hanbin Zhang, Liuyi Yao, Huining Li, Chenhan Xu, Zhengxiong Li & Wenyao Xu. (2021) MSLife. Proceedings of the ACM on Interactive, Mobile, Wearable and Ubiquitous Technologies 5:4, pages 1-35.
Crossref
Crossref
Yazed AlRuthia, Bander Balkhi, Sahar Abdullah Alkhalifah, Salman Aljarallah, Lama Almutairi, Miteb Alanazi, Abdulmalik Alajlan, Suliman M. Aldhafiri & Nuha M. Alkhawajah. (2021) Real-World Comparative Cost-Effectiveness Analysis of Different Classes of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in Saudi Arabia. International Journal of Environmental Research and Public Health 18:24, pages 13261.
Crossref
Crossref
Diana M. Sima, Giovanni Esposito, Wim Van Hecke, Annemie Ribbens, Guy Nagels & Dirk Smeets. (2021) Health Economic Impact of Software-Assisted Brain MRI on Therapeutic Decision-Making and Outcomes of Relapsing-Remitting Multiple Sclerosis Patients—A Microsimulation Study. Brain Sciences 11:12, pages 1570.
Crossref
Crossref
Justin R. Abbatemarco, Jeffrey A. Cohen, Belinda L. UdehSunakshi BassiMary R. Rensel. (2021) Multiple Sclerosis Wellness Shared Medical Appointment Model. International Journal of MS Care 23:5, pages 229-233.
Crossref
Crossref
Flavia Senkubuge, Charles Hongoro & Joses Muthuri Kirigia. (2021) Dollar value of disability-adjusted life years in South Africa in 2019. Journal of Global Health Economics and Policy 1.
Crossref
Crossref
Serena Brancati, Lucia Gozzo, Laura Longo, Daniela Cristina Vitale & Filippo Drago. (2021) Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?. Frontiers in Immunology 12.
Crossref
Crossref
Marco Pisa, Raffaella Chieffo, Martina Congiu, Gloria Dalla Costa, Federica Esposito, Marzia Romeo, Mauro Comola, Giancarlo Comi & Letizia Leocani. (2020) Intracortical motor conduction is associated with hand dexterity in progressive multiple sclerosis. Multiple Sclerosis Journal 27:8, pages 1222-1229.
Crossref
Crossref
Jalal Dahham, Rana Rizk, Ingrid Kremer, Silvia M. A. A. Evers & Mickaël Hiligsmann. (2021) Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review. PharmacoEconomics 39:7, pages 789-807.
Crossref
Crossref
Daniel M. Hartung. (2021) Economics of Multiple Sclerosis Disease-Modifying Therapies in the USA. Current Neurology and Neuroscience Reports 21:7.
Crossref
Crossref
Edward E. Neuberger, Ibrahim M. Abbass, Eddie Jones & Natalie J. Engmann. (2020) Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis. Neurology and Therapy 10:1, pages 183-196.
Crossref
Crossref
Hui Lu, Peng-Fei Wu, Wan Zhang & Xiaoyao Liao. (2021) Circulating Interleukins and Risk of Multiple Sclerosis: A Mendelian Randomization Study. Frontiers in Immunology 12.
Crossref
Crossref
Machaon Bonafede, Rina Mehta, Gilwan Kim, Ila Sruti, Marc Tian, Corey Pelletier & Neil Goldfarb. (2020) Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis. PharmacoEconomics - Open 5:1, pages 23-34.
Crossref
Crossref
Tobore Onojighofia Tobore. (2020) Oxidative/Nitroxidative Stress and Multiple Sclerosis. Journal of Molecular Neuroscience 71:3, pages 506-514.
Crossref
Crossref
Jian Zhang, Shengliang Shi, Yueling Zhang, Jiefeng Luo, Jian Tang & Jinglian Luo. (2021) Ozanimod for relapsing-remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2022:4.
Crossref
Crossref
Daniel M. Hartung. (2021) Health economics of disease-modifying therapy for multiple sclerosis in the United States. Therapeutic Advances in Neurological Disorders 14, pages 175628642098703.
Crossref
Crossref
Edgar Carnero Contentti, Susana Giachello & Jorge Correale. (2020) Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients. Multiple Sclerosis Journal 27:1, pages 117-129.
Crossref
Crossref
Stefano Cerri, Oula Puonti, Dominik S. Meier, Jens Wuerfel, Mark Mühlau, Hartwig R. Siebner & Koen Van Leemput. (2021) A contrast-adaptive method for simultaneous whole-brain and lesion segmentation in multiple sclerosis. NeuroImage 225, pages 117471.
Crossref
Crossref
Ram N. Narayan, Olaf Stüve & Anjali Shah. 2021. Braddom's Physical Medicine and Rehabilitation. Braddom's Physical Medicine and Rehabilitation
983
1005.e5
.
Daniel M. Hartung, Kirbee A. Johnston, Jessina C. McGregor & Dennis N. Bourdette. (2020) The effect of out-of-pocket costs on initiation of disease-modifying therapies among medicare beneficiaries with multiple sclerosis. Multiple Sclerosis and Related Disorders 46, pages 102554.
Crossref
Crossref
Karol Perlejewski, Iwona Bukowska-Ośko, Małgorzata Rydzanicz, Tomasz Dzieciątkowski, Beata Zakrzewska-Pniewska, Aleksandra Podlecka-Piętowska, Agata Filipiak, Krzysztof Barć, Kamila Caraballo Cortés, Agnieszka Pawełczyk, Marek Radkowski & Tomasz Laskus. (2020) Search for viral agents in cerebrospinal fluid in patients with multiple sclerosis using real-time PCR and metagenomics. PLOS ONE 15:10, pages e0240601.
Crossref
Crossref
Richard K Burt, Paul Tappenden, Xiaoqiang Han, Kathleen Quigley, Indira Arnautovic, Basil Sharrack, John A Snowden & Daniel Hartung. (2020) Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America. Multiple Sclerosis and Related Disorders 45, pages 102404.
Crossref
Crossref
Katharina Heß, Laura Starost, Nicholas W. Kieran, Christian Thomas, Maria C. J. Vincenten, Jack Antel, Gianvito Martino, Inge Huitinga, Luke Healy & Tanja Kuhlmann. (2020) Lesion stage-dependent causes for impaired remyelination in MS. Acta Neuropathologica 140:3, pages 359-375.
Crossref
Crossref
Maria Paz-Zulueta, Paula Parás-Bravo, David Cantarero-Prieto, Carla Blázquez-Fernández & Agustín Oterino-Durán. (2020) A literature review of cost-of-illness studies on the economic burden of multiple sclerosis.. Multiple Sclerosis and Related Disorders 43, pages 102162.
Crossref
Crossref
Zehui Liu, Qian Hu, Wanyan Wang, Sisi Lu, Dang Wu, Shuyin Ze, Jiacheng He, Ying Huang, Wuyan Chen, Yechun Xu, Weiqiang Lu & Jin Huang. (2020) Natural product piperine alleviates experimental allergic encephalomyelitis in mice by targeting dihydroorotate dehydrogenase. Biochemical Pharmacology 177, pages 114000.
Crossref
Crossref
Jagadeswara Rao EarlaJ. Douglas ThorntonGeorge J. HuttonRajender R. Aparasu. (2020) Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015. Journal of Managed Care & Specialty Pharmacy 26:6, pages 741-749.
Crossref
Crossref
Elizabeth Silbermann, Angela Senders, Lindsey Wooliscroft, Jessica Rice, Michelle Cameron, Carin Waslo, Anna Orban, Emma Chase, Vijayshree Yadav, Dennis Bourdette & Rebecca I Spain. (2020) Cross-sectional survey of complementary and alternative medicine used in Oregon and Southwest Washington to treat multiple sclerosis: A 17-Year update. Multiple Sclerosis and Related Disorders 41, pages 102041.
Crossref
Crossref
Sumire Sato, Jongil Lim, Jules D. Miehm, John Buonaccorsi, Caitlin Rajala, Farnaz Khalighinejad, Carolina Ionete, Jane A. Kent & Richard E.A. van Emmerik. (2020) Rapid foot-tapping but not hand-tapping ability is different between relapsing-remitting and progressive multiple sclerosis. Multiple Sclerosis and Related Disorders 41, pages 102031.
Crossref
Crossref
Begum Irmak On Seker, Kelly Reeve, Joachim Havla, Jacob Burns, Martina A Gosteli, Andreas Lutterotti, Sven Schippling, Ulrich Mansmann & Ulrike Held. (2020) Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Julie Havas, Emmanuelle Leray, Fabien Rollot, Romain Casey, Laure Michel, Flora Lejeune, Sandrine Wiertlewski, David Laplaud & Yohann Foucher. (2020) Predictive medicine in multiple sclerosis: A systematic review. Multiple Sclerosis and Related Disorders 40, pages 101928.
Crossref
Crossref
Faeze Rouhi, Zinat Mohammadpour, Sakineh Kazemi Noureini, Hedayat Abbastabar, Mohammad Hossein Harirchian & Sama Bitarafan. (2020) The effects and side effects of laquinimod for the treatment of multiple sclerosis patients: a systematic review and meta-analysis of clinical trials. European Journal of Clinical Pharmacology 76:5, pages 611-622.
Crossref
Crossref
Tanuja Chitnis & Alexandre Prat. (2020) A roadmap to precision medicine for multiple sclerosis. Multiple Sclerosis Journal 26:5, pages 522-532.
Crossref
Crossref
Venu Talla & Rajeshwari Koilkonda. (2020) Targeted Krüppel-Like Factor 4 Gene Knock-Out in Retinal Ganglion Cells Improves Visual Function in Multiple Sclerosis Mouse Model. eneuro 7:2, pages ENEURO.0320-19.2020.
Crossref
Crossref
Chungyi Chiu, Malachy Bishop, Bradley McDaniels, Byung-Jin Kim & Lebogang Tiro. (2018) A Population-Based Investigation of Health-Care Needs and Preferences in American Adults With Multiple Sclerosis. Journal of Patient Experience 7:1, pages 34-41.
Crossref
Crossref
Tobore Onojighofia Tobore. (2019) On elucidation of the role of mitochondria dysfunction and oxidative stress in multiple sclerosis. Neurology and Clinical Neuroscience 7:6, pages 305-317.
Crossref
Crossref
Andrew C. Chan, Paul Brunetta & Peter Chin. 2019. Successful Drug Discovery. Successful Drug Discovery
169
199
.
Brandon P Moss & Jeffrey A Cohen. (2019) The emergence of follow-on disease-modifying therapies for multiple sclerosis. Multiple Sclerosis Journal 25:12, pages 1560-1565.
Crossref
Crossref
Richard S Nicholas, Erika Han, Joel Raffel, Jeremy Chataway & Tim Friede. (2018) Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials. Multiple Sclerosis Journal 25:11, pages 1462-1471.
Crossref
Crossref
A. Hosseinzadeh, M.R. Baneshi, B. Sedighi, J. Kermanchi & A.A. Haghdoost. (2019) Incidence of multiple sclerosis in Iran: a nationwide, population-based study. Public Health 175, pages 138-144.
Crossref
Crossref
Natasha Frost, Jerome Freeman, Diana Brixner, Jane Mort, James Clem & Surachat Ngorsuraches. (2019) Patients’ preferences and willingness-to-pay for disease-modifying therapies. Multiple Sclerosis and Related Disorders 35, pages 55-60.
Crossref
Crossref
Anastasie M. Dunn-Pirio, Benjamin M. Heyman, Dan S. Kaufman & Revere P. Kinkel. (2019) Outcomes and Cost-Effectiveness of Autologous Hematopoietic Cell Transplant for Multiple Sclerosis. Current Treatment Options in Neurology 21:10.
Crossref
Crossref
Maryam S. Alowayesh, Samar F. Ahmed, Jasem Al-Hashel & Raed Alroughani. (2019) Economic burden of multiple sclerosis on Kuwait health care system. PLOS ONE 14:5, pages e0216646.
Crossref
Crossref
Nadine Nagy, Hedwich F. Kuipers, Payton L. Marshall, Esther Wang, Gernot Kaber & Paul L. Bollyky. (2019) Hyaluronan in immune dysregulation and autoimmune diseases. Matrix Biology 78-79, pages 292-313.
Crossref
Crossref
Viktor Chirikov, Ingrid Ma, Namita Joshi, Dipen Patel, Alden Smith, Cindy Giambrone, Noelle Cornelio & Lobat Hashemi. (2019) Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States. Value in Health 22:2, pages 168-176.
Crossref
Crossref
Kevin J. Peine, Naihan Chen, Eric M. Bachelder & Kristy M. Ainslie. 2019. Chronic Illness and Long-Term Care. Chronic Illness and Long-Term Care
112
140
.
Pauline Luczynski, Cornelia Laule, Ging-Yuek Robin Hsiung, G.R. Wayne Moore & Helen Tremlett. (2019) Coexistence of Multiple Sclerosis and Alzheimer's disease: A review. Multiple Sclerosis and Related Disorders 27, pages 232-238.
Crossref
Crossref
Vignesh Kotian, Leela Mounica, Deepaneeta Sarmah, Harpreet Kaur, Geetesh Verma, Radhika Kesharwani, Pabbala Veeresh, Anupom Borah, Kiran Kalia & Pallab Bhattacharya. 2019. Biomedical Engineering and its Applications in Healthcare. Biomedical Engineering and its Applications in Healthcare
597
617
.
Yuriko Adkins, Athena M. Soulika, Bruce Mackey & Darshan S. Kelley. (2019) Docosahexaenoic acid (22:6n‐3) Ameliorated the Onset and Severity of Experimental Autoimmune Encephalomyelitis in Mice. Lipids 54:1, pages 13-23.
Crossref
Crossref
Ivan Mauricio Muñoz-Galindo, Jairo Alexander Moreno Calderón, Natalia Elizabeth Guarín Téllez, Helbert Orlando Arévalo Roa & Jorge Augusto Díaz Rojas. (2018) Health Care Cost for Multiple Sclerosis: The Case of a Health Insurer in Colombia. Value in Health Regional Issues 17, pages 14-20.
Crossref
Crossref
B. Svendsen, N. Grytten, L. Bø, H. Aarseth, T. Smedal & K-M. Myhr. (2018) The economic impact of multiple sclerosis to the patients and their families in Norway. The European Journal of Health Economics 19:9, pages 1243-1257.
Crossref
Crossref
Petra Maresova, Martin Valis, Michal Novotny, Zbyšek Pavelek & Kamil Kuca. (2018) The direct costs of multiple sclerosis—study in the Czech Republic. Neurological Sciences 39:12, pages 2115-2121.
Crossref
Crossref
Kristina F Simacek, John J Ko, Debbie Moreton, Stefan Varga, Kristen Johnson & Bozena J Katic. (2018) The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study. Journal of Medical Internet Research 20:10, pages e11168.
Crossref
Crossref
Kelly Claire Simon, Afif Hentati, Susan Rubin, Tiffani Franada, Darryck Maurer, Laura Hillman, Samuel Tideman, Monika Szela, Steven Meyers, Roberta Frigerio & Demetrius M Maraganore. (2018) Successful utilization of the EMR in a multiple sclerosis clinic to support quality improvement and research initiatives at the point of care. Multiple Sclerosis Journal - Experimental, Translational and Clinical 4:4, pages 205521731881373.
Crossref
Crossref
Andrew Hresko, Tzu-Chieh Lin & Daniel H. Solomon. (2018) Medical Care Costs Associated With Rheumatoid Arthritis in the US: A Systematic Literature Review and Meta-Analysis. Arthritis Care & Research 70:10, pages 1431-1438.
Crossref
Crossref
Bailey Winter, Samuel Daniels, Joseph Salatino & Erin Purcell. (2018) Genetic Modulation at the Neural Microelectrode Interface: Methods and Applications. Micromachines 9:10, pages 476.
Crossref
Crossref
Guillermo Borragán, Médhi Gilson, Anne Atas, Hichem Slama, Andreas Lysandropoulos, Melanie De Schepper & Philippe Peigneux. (2018) Cognitive Fatigue, Sleep and Cortical Activity in Multiple Sclerosis Disease. A Behavioral, Polysomnographic and Functional Near-Infrared Spectroscopy Investigation. Frontiers in Human Neuroscience 12.
Crossref
Crossref
B. Casey, S. Coote, R. Galvin & A. Donnelly. (2018) Objective physical activity levels in people with multiple sclerosis: Meta-analysis. Scandinavian Journal of Medicine & Science in Sports 28:9, pages 1960-1969.
Crossref
Crossref
Leigh Charvet, Michael Shaw, Bryan Dobbs, Ariana Frontario, Kathleen Sherman, Marom Bikson, Abhishek Datta, Lauren Krupp, Esmail Zeinapour & Margaret Kasschau. (2018) Remotely Supervised Transcranial Direct Current Stimulation Increases the Benefit of At-Home Cognitive Training in Multiple Sclerosis. Neuromodulation: Technology at the Neural Interface 21:4, pages 383-389.
Crossref
Crossref
Jay Visaria, Nina Thomas, Tao Gu, Joseph Singer & Hiangkiat Tan. (2018) Understanding the Patient's Journey in the Diagnosis and Treatment of Multiple Sclerosis in Clinical Practice. Clinical Therapeutics 40:6, pages 926-939.
Crossref
Crossref
Marti GroenewegSara H. ForresterBeth ArnoldLorella PalazzoWeiwei ZhuPaul YoonTim Scearce. (2018) One-Year Outcomes of an Integrated Multiple Sclerosis Disease Management Program. Journal of Managed Care & Specialty Pharmacy 24:5, pages 458-463.
Crossref
Crossref
Jacqueline Nicholas, Aaron Boster, Ning Wu, Wei-Shi Yeh, Monica Fay, Jon Kendter, Ming-Yi Huang & Andrew Lee. (2017) Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data. PharmacoEconomics - Open 2:1, pages 31-41.
Crossref
Crossref
Daniel S. Reich, Claudia F. LucchinettiPeter A. Calabresi. (2018) Multiple Sclerosis. New England Journal of Medicine 378:2, pages 169-180.
Crossref
Crossref
Mohd Izmi Bin Ahmad. 2018. Braddom's Rehabilitation Care: A Clinical Handbook. Braddom's Rehabilitation Care: A Clinical Handbook
326
332.e12
.
Bahman JabbariBahman Jabbari. 2018. Botulinum Toxin Treatment. Botulinum Toxin Treatment
75
86
.
Yasaman Safarpour & Bahman Jabbari. 2018. Botulinum Toxin Treatment in Clinical Medicine. Botulinum Toxin Treatment in Clinical Medicine
109
129
.
Antoni Sicras-Mainar, Elena Ruíz-Beato, Ruth Navarro-Artieda & Jorge Maurino. (2017) Impact on healthcare resource utilization of multiple sclerosis in Spain. BMC Health Services Research 17:1.
Crossref
Crossref
Chungyi Chiu, Malachy Bishop, J.J. Pionke, David Strauser & Ryan L. Santens. (2017) Barriers to the Accessibility and Continuity of Health-Care Services in People with Multiple Sclerosis. International Journal of MS Care 19:6, pages 313-321.
Crossref
Crossref
Mai F. Alsaqa’aby, Varun Vaidya, Noura Khreis, Thamer Al Khairallah & Ahmed H. Al-jedai. (2017) Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia. Annals of Saudi Medicine 37:6, pages 433-443.
Crossref
Crossref
Maryam Abbasi, Seyed Massood Nabavi, Seyed Mohammad Fereshtehnejad, Nikan Zerafat Jou, Iman Ansari, Vahid Shayegannejad, Seyed Ehsan Mohammadianinejad, Mahdi Farhoudi, Abbas Noorian, Nazanin Razazian, Mahmoud Abedini & Fardin Faraji. (2017) Multiple sclerosis and environmental risk factors: a case-control study in Iran. Neurological Sciences 38:11, pages 1941-1951.
Crossref
Crossref
Daniel M. Hartung. (2017) Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA. Neurotherapeutics 14:4, pages 1018-1026.
Crossref
Crossref
Brandon P. Moss, Mary R. Rensel & Carrie M. Hersh. (2017) Wellness and the Role of Comorbidities in Multiple Sclerosis. Neurotherapeutics 14:4, pages 999-1017.
Crossref
Crossref
Andrew L. Smith, Jeffrey A. Cohen & Le H. Hua. (2017) Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions. Neurotherapeutics 14:4, pages 952-960.
Crossref
Crossref
Yasaman Safarpour, Tahereh Mousavi & Bahman Jabbari. (2017) Botulinum Toxin Treatment in Multiple Sclerosis—a Review. Current Treatment Options in Neurology 19:10.
Crossref
Crossref
Laney K. Jones, Gerard Greskovic, Dante M. Grassi, Jove Graham, Haiyan Sun, Michael R. Gionfriddo, Michael F. Murray, Kandamurugu Manickam, Douglas C. Nathanson, Eric A. Wright & Michael A. Evans. (2017) Medication therapy disease management: Geisinger’s approach to population health management. American Journal of Health-System Pharmacy 74:18, pages 1422-1435.
Crossref
Crossref
Delphine Lefeuvre, Jérémie Rudant, Stéphanie Foulon, François Alla & Alain Weill. (2017) Healthcare expenditure of multiple sclerosis patients in 2013: A nationwide study based on French health administrative databases. Multiple Sclerosis Journal - Experimental, Translational and Clinical 3:3, pages 205521731773042.
Crossref
Crossref
Cory M. Willis, Antoine Ménoret, Evan R. Jellison, Alexandra M. Nicaise, Anthony T. Vella & Stephen J. Crocker. (2017) A Refined Bead-Free Method to Identify Astrocytic Exosomes in Primary Glial Cultures and Blood Plasma. Frontiers in Neuroscience 11.
Crossref
Crossref
Diana L Vargas & William R Tyor. (2023) Update on Disease-Modifying Therapies for Multiple Sclerosis. Journal of Investigative Medicine 65:5, pages 883-891.
Crossref
Crossref
Jee-Eun Kim, Kang M. Park, Yerim Kim, Dae Y. Yoon & Jong S. Bae. (2017) Citation classics in central nervous system inflammatory demyelinating disease. Brain and Behavior 7:6, pages e00700.
Crossref
Crossref
Tom MunyerGrace Minassian. 2017. PharmacotherapyFirst: A Multimedia Learning Resource. PharmacotherapyFirst: A Multimedia Learning Resource.
A. Nandoskar, J. Raffel, A. S. Scalfari, T. Friede & R. S. Nicholas. (2017) Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis. Drugs 77:8, pages 885-910.
Crossref
Crossref
Naihan Chen, Kevin J. Peine, Michael A. Collier, Shalini Gautam, Kyle A. Jablonski, Mireia Guerau-de-Arellano, Kristy M. Ainslie & Eric M. Bachelder. (2017) Co-Delivery of Disease Associated Peptide and Rapamycin via Acetalated Dextran Microparticles for Treatment of Multiple Sclerosis. Advanced Biosystems 1:3, pages 1700022.
Crossref
Crossref
Andrius Kavaliunas, Ali Manouchehrinia, Virginija Danylaite Karrenbauer, Hanna Gyllensten, Anna Glaser, Kristina Alexanderson & Jan Hillert. (2017) Income in Multiple Sclerosis Patients with Different Disease Phenotypes. PLOS ONE 12:1, pages e0169460.
Crossref
Crossref
Keying Zhu, Jingxian Sun, Zheng Kang, Zaofeng Zou, Gencheng Wu & Jun Wang. (2017) Electroacupuncture Promotes Remyelination after Cuprizone Treatment by Enhancing Myelin Debris Clearance. Frontiers in Neuroscience 10.
Crossref
Crossref
Ritchie Chen, Andres Canales & Polina Anikeeva. (2017) Neural recording and modulation technologies. Nature Reviews Materials 2:2.
Crossref
Crossref
Laurence Knowles. (2017) The Evolution of Myelin: Theories and Application to Human Disease. Journal of Evolutionary Medicine 5, pages 1-23.
Crossref
Crossref
Kevin J. Peine, Naihan Chen, Eric M. Bachelder & Kristy M. Ainslie. 2017. Recent Advances in Drug Delivery Technology. Recent Advances in Drug Delivery Technology
23
51
.
Peter W. ParkRichard D. DryerRozelle Hegeman-DingleJack MardekianGergana ZlatevaGreg G. WolffLois E. Lamerato. (2016) Cost Burden of Chronic Pain Patients in a Large Integrated Delivery System in the United States. Pain Practice 16:8, pages 1001-1011.
Crossref
Crossref
Lindsey Zeplin & Stephen Lott. (2016) Specialty disease states: Understanding the true costs of care. Pharmacy Today 22:10, pages 61.
Crossref
Crossref
Feng Yang, Edson F. Estrada & Maria C. Sanchez. (2016) Vibration training improves disability status in multiple sclerosis: A pretest-posttest pilot study. Journal of the Neurological Sciences 369, pages 96-101.
Crossref
Crossref
Le H. HuaJeffrey A. Cohen. (2016) Considerations in the development of generic disease therapies for multiple sclerosis. Neurology Clinical Practice 6:4, pages 369-376.
Crossref
Crossref
John A. Olsen, Lauren A. Kenna, Regine C. Tipon, Michael G. Spelios, Mark M. Stecker & Eitan M. Akirav. (2016) A Minimally-invasive Blood-derived Biomarker of Oligodendrocyte Cell-loss in Multiple Sclerosis. eBioMedicine 10, pages 227-235.
Crossref
Crossref
Olivia Ernstsson, Hanna Gyllensten, Kristina Alexanderson, Petter Tinghög, Emilie Friberg & Anders Norlund. (2016) Cost of Illness of Multiple Sclerosis - A Systematic Review. PLOS ONE 11:7, pages e0159129.
Crossref
Crossref
Anush Karamyan, Martin W. Dünser, Douglas J. Wiebe, Georg Pilz, Peter Wipfler, Vaclav Chroust, Helmut F. Novak, Larissa Hauer, Eugen Trinka & Johann Sellner. (2016) Critical Illness in Patients with Multiple Sclerosis: A Matched Case-Control Study. PLOS ONE 11:5, pages e0155795.
Crossref
Crossref
Piyameth DilokthornsakulRobert J. ValuckKavita V. NairJohn R. CorboyRichard R. AllenJonathan D. Campbell. (2016) Multiple sclerosis prevalence in the United States commercially insured population. Neurology 86:11, pages 1014-1021.
Crossref
Crossref
Stefan Viktor Vormfelde, Sonja Ortler & Tjalf Ziemssen. (2016) Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol. JMIR Research Protocols 5:1, pages e23.
Crossref
Crossref
Wenbin Liao, Victor Pham, Linan Liu, Milad Riazifar, Egest J. Pone, Shirley Xian Zhang, Fengxia Ma, Mengrou Lu, Craig M. Walsh & Weian Zhao. (2016) Mesenchymal stem cells engineered to express selectin ligands and IL-10 exert enhanced therapeutic efficacy in murine experimental autoimmune encephalomyelitis. Biomaterials 77, pages 87-97.
Crossref
Crossref
Andrius Kavaliunas, Michael Wiberg, Petter Tinghög, Anna Glaser, Hanna Gyllensten, Kristina Alexanderson & Jan Hillert. (2015) Earnings and Financial Compensation from Social Security Systems Correlate Strongly with Disability for Multiple Sclerosis Patients. PLOS ONE 10:12, pages e0145435.
Crossref
Crossref
Alexander Rae-GrantAmy BennettAmy E. SandersMichael PhippsEric ChengChristopher Bever. (2015) Quality improvement in neurology: Multiple sclerosis quality measures. Neurology 85:21, pages 1904-1908.
Crossref
Crossref
Mojtaba Farjam, Guang-Xian Zhang, Bogoljub Ciric & Abdolmohamad Rostami. (2015) Emerging immunopharmacological targets in multiple sclerosis. Journal of the Neurological Sciences 358:1-2, pages 22-30.
Crossref
Crossref
Gavin Giovannoni, Ralf Gold, Robert J. Fox, Ludwig Kappos, Mariko Kita, Minhua Yang, Sujata P. Sarda, Ray Zhang, Vissia Viglietta & Eva Havrdova. (2015) Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis–related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies. Clinical Therapeutics 37:11, pages 2543-2551.
Crossref
Crossref
Jack Hutcheson. (2015) Adipokines influence the inflammatory balance in autoimmunity. Cytokine 75:2, pages 272-279.
Crossref
Crossref
Richard E. Nelson, Yan Xie, Scott L. DuVall, Jorie Butler, Aaron W. C. Kamauu, Kristin Knippenberg, Markus Schuerch, Nadia Foskett & Joanne LaFleur. (2015) Multiple Sclerosis and Risk of Infection-Related Hospitalization and Death in US Veterans. International Journal of MS Care 17:5, pages 221-230.
Crossref
Crossref
Sylvia Klineova, Nesanet Mitiku & Aaron E Miller. (2015) Disease-modifying therapy for multiple sclerosis. Future Neurology 10:3, pages 253-279.
Crossref
Crossref
Denis Bernardi Bichuetti, Alessandra Billi Falcão, Fernanda de Castro Boulos, Marilia Mamprim de Morais, Claudia Beatriz de Campos Lotti, Manuela de Oliveira Fragomeni, Maria Fernanda Campos, Nilton Amorim de Souza & Enedina Maria Lobato Oliveira. (2015) The profile of patients followed at the Neuroimmunology Clinic at UNIFESP: 20 years analysis. Arquivos de Neuro-Psiquiatria 73:4, pages 304-308.
Crossref
Crossref
Marcus W. Koch, T. Jock Murray, John Fisk, Jamie Greenfield, Virender Bhan, Philip Jacobs, Murray Brown & Luanne M. Metz. (2014) Hand dexterity and direct disease related cost in multiple sclerosis. Journal of the Neurological Sciences 341:1-2, pages 51-54.
Crossref
Crossref
Vincent Y. Ma, Leighton Chan & Kadir J. Carruthers. (2014) Incidence, Prevalence, Costs, and Impact on Disability of Common Conditions Requiring Rehabilitation in the United States: Stroke, Spinal Cord Injury, Traumatic Brain Injury, Multiple Sclerosis, Osteoarthritis, Rheumatoid Arthritis, Limb Loss, and Back Pain. Archives of Physical Medicine and Rehabilitation 95:5, pages 986-995.e1.
Crossref
Crossref
James E. Pease & Richard Horuk. 2015. Chemokines. Chemokines
1
39
.